{"id":"NCT00250432","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)","officialTitle":"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2008-01","completion":"2008-03","firstPosted":"2005-11-08","resultsPosted":"2009-03-24","lastUpdate":"2017-03-24"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Invasive Candidiasis"],"interventions":[{"type":"DRUG","name":"caspofungin acetate","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)","primaryOutcome":{"measure":"Number of Patients Who Develop Significant Drug-related Adverse Events.","timeFrame":"90 Days","effectByArm":[{"arm":"Caspofungin 70/50 mg","deltaMin":2,"sd":null},{"arm":"Caspofungin 150 mg","deltaMin":3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19419331"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46},"commonTop":["Blood Alkaline Phosphatase Increased","Vomiting","Aspartate Aminotransferase Increased","Blood Potassium Decreased","Diarrhea"]}}